about
Targeted Therapy for Older Patients with Uncontrolled Severe Asthma: Current and Future Prospects.Lebrikizumab for the treatment of asthma.Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials.Essential Mechanisms of Differential Activation of Eosinophils by IL-3 Compared to GM-CSF and IL-5.Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma.Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease.Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.
P2860
Q38820261-751405FE-75F3-49ED-8010-CFDBE51DF332Q38935585-0612D28B-8DD2-44B9-A822-013268D2E4EFQ39012366-7A444B52-19A0-4667-BF61-14A530248FC5Q39366933-E31CC904-EBAC-4C74-92F7-2ECBF4F4235AQ41605623-7FAD0998-660E-4D69-853D-0015BC145E9DQ47786031-7E6EA68D-D6EB-4A03-BE3C-F1C6E54DAA5CQ49751199-FCE813F9-CDFA-4221-887A-BFC40D34E46CQ52571066-468C3A77-C3AB-4C39-BE6C-16D12F298933
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Mepolizumab: First Global Approval.
@en
type
label
Mepolizumab: First Global Approval.
@en
prefLabel
Mepolizumab: First Global Approval.
@en
P2860
P1433
P1476
Mepolizumab: First Global Approval.
@en
P2860
P2888
P304
P356
10.1007/S40265-015-0513-8
P577
2015-11-24T00:00:00Z
P6179
1033640868